Julia Hardick, M.Sc.

Position: PhD Student

Room no.: CP-02-110

Telephone no.: +49 (0)231 755 7053


Member of the group since: 11/2015

University degree: M.Sc. in Chemical Biology, TU Dortmund University


Earlier positions: Bachelor and master studies in the group of Daniel Rauh on the MAPK p38α

Expertise: organic synthesis, pharmacokinetics (drug metabolism studies)

Off-Lab activities (hobbies): badminton, inline skating

Research projects:

The research project contains structure-based design, organic synthesis and the determination of synthesized compounds in a pharmacokinetic context, such as the identification of metabolic stability in a phase I metabolism assay as well as plasma stability.
Regarding the synthesis part of my work I focused on Her2, a member of the human epidermal growth factor receptor family, which overexpression has been shown to act as a key player in breast cancer. A second synthesis project deals with the mitogen activated protein kinase kinase 7 (MKK7) and the evaluation of covalent inhibitors to target the JNK-pathway. Both kinases represent attractive targets in drug discovery and offer fascinating medicinal chemistry projects.


  1. Kaitsiotou, H., Keul, M., Hardick, J., T. Mühlenberg, T., Ketzer, J., Ehrt, C., Krüll, J., Medda, F., Koch, O., Giordanett, F., Bauer S., Rauh D., Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT. J Med Chem, 2017, 60(21):8801-15.
  2. Bührmann, M., Hardick, J., Weisner, J., Quambusch, L., Rauh, D., Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Angew Chem Int Ed Engl, 2017, 56(43):13232-36.
  3. Bührmann, M., Wiedemann, B. M., Müller, M.P., Hardick, J., Ecke, M., Rauh, D., Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PLoS ONE, 2017, 12(9):e0184627.